Group 1: Company Overview and Operations - The company has acquired the American health supplement brand DRB, which is known for its high-quality dietary supplements and has a significant presence on platforms like Amazon and iHerb [3][4]. - The acquisition includes a fully-owned subsidiary, VitaBest Nutrition, Inc., which has nearly 50 years of experience and offers contract manufacturing services in a pharmaceutical-grade environment [3][4]. Group 2: Future Sales Plans - The Doctor's Best brand products are primarily sold through cross-border e-commerce platforms and flagship stores on JD and Tmall, aiming to enhance brand influence in both domestic and international markets [4]. - The marketing team is actively exploring diverse sales channels and partnerships to expand market reach [4]. Group 3: Strategic Investments - The investment in Shanghai Ranka Trading Co., Ltd. aims to integrate high-quality resources from the sports and nutrition industries, leveraging e-commerce and community operations for product promotion [5]. - This strategic move is expected to enhance the company's resilience and support long-term development [5]. Group 4: Impact of Vitamin Price Increases - Post-Chinese New Year, there has been a significant price increase in Vitamin A and D3 due to supply constraints and regulatory factors, which is anticipated to positively impact the company's performance in the first half of the year [5]. - However, since vitamins represent only 60-70% of the company's market, the correlation between domestic price increases and overall performance growth should not be overstated [5].

Group 1: Company Performance and Challenges - The significant decline in 2015 performance was largely due to a sharp drop in vitamin prices, which has since rebounded in early 2016 [2][3] - The company is currently in a transformation phase, facing challenges in promoting new brands and products, which require substantial sales expenses and involve uncertainties in new business and profit models [3][4] - The health products market in China experienced a CAGR of 15% from 2012 to 2014, significantly higher than the 7% CAGR from 2008 to 2012, driven by factors such as aging population and rising consumer spending [4] Group 2: Strategic Initiatives and Market Position - The company is actively expanding its global sales channels through acquisitions, such as the American health product brand Doctor's Best, and establishing subsidiaries like VitaBest [4][5] - The company aims to diversify its operations from a B2B model to include B2C sales, enhancing its market presence in the health product sector [6][17] - The company has over 200 health product varieties under the DRB brand, indicating a broad product range in the market [17] Group 3: Financial Outlook and Investor Relations - The company is focused on maximizing shareholder value and aims for a net profit growth rate in 2016, although specific predictions cannot be disclosed [12][45] - The management emphasizes the importance of maintaining a stable executive team and is optimistic about the company's future growth prospects [8][18] - The company plans to increase marketing efforts and expand sales channels to boost performance, which may lead to higher marketing expenses [15]

Group 1: Company Operations - The overseas subsidiaries acquired by the company have achieved a smooth transition, and future operations are expected to maintain a good development outlook [1][2] - The company aims to create a closer complementary and synergistic relationship with its existing business system, effectively saving management costs and enhancing overall competitive capability [2] Group 2: Pricing Strategies - The company will implement effective pricing strategies for Coenzyme Q10 based on actual market conditions to fully leverage its leading position in this product [2] - The price of Vitamin A products has seen significant increases due to concentrated supply and rigid demand, alongside supply-side reforms and stricter environmental regulations [2] Group 3: Financial Impact - The market for Vitamin A products is expected to remain at historically high levels, which is anticipated to contribute significantly to the company's profits [2]

证券代码：002626 证券简称：金达威 厦门金达威集团股份有限公司投资者关系活动记录表 编号：20170512 | --- | --- | --- | --- | --- | |-----------------|--------------------------------------|--------------------------------------------------------|-------|-----------------| | | | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | 参与单位名称及 | 华泰证券股份有限公司 | 研究所 食品饮料研究员李晴 | | | | 人员姓名 | 华泰证券股份有限公司 | 研究所 食品饮料高级研究员 | | 贺琪 | | 时间 2017 | 年 5 月 12 日上午 | | | | | 地点 公司会议室 ...

证券代码：002626 证券简称：金达威 厦门金达威集团股份有限公司投资者关系活动记录表 编号：20170620 | --- | --- | --- | --- | --- | |-------------------------|--------------------------------------------------------|----------------------------------------------------|------------------------|----------| | | | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 参与单位名称及 人员姓名 | 中国中投证券有限责任公司 | 财富研究部 | 行业研究员 | 刘思远 | | 时间 2017 | 年 6 月 20 日上午 | | | | | 地点 | 公司会议室 | ...

证券代码：002626 证券简称：金达威 厦门金达威集团股份有限公司投资者关系活动记录表 编号：20161228 | --- | --- | --- | --- | --- | |-----------------------|----------------------------|--------------------------------------------------------|------------------|---------------------| | | | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | | | 类别 | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | 参与单位名称及 | | 弘则弥道（上海）投资咨询有限责任公司 | | 消费分析师 龚源月 | | 人员姓名 | | 弘则弥道（上海）投资咨询有限责任公司 | | 首席分析师 霍健 | | | 国泰君安证券股份有限公司 | 研究所 | 互联网传 ...

证券代码：002626 证券简称：金达威 厦门金达威集团股份有限公司投资者关系活动记录表 编号：20170110 | --- | --- | --- | --- | --- | |-------------------------|--------------------------------------------------------|----------------------------------------------------|-------|--------------------| | | | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | 参与单位名称及 人员姓名 | 中泰证券股份有限公司 | 研究所 食品饮料研究员 | | 张喆 | | 时间 2017 | 年 1 月 10 日上午 | | | | | 地点 公司会议室 | | | | | | 上市 ...

证券代码： 002626 证券简称：金达威 编号：20200522 20200522 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ☑ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 西南证券研究发展中心 周峰春 | | | 人员姓名 | 长城证券 苏剑晓 | | | | 天朗资产管理 罗继明 | | | | | 道生（福建）投资有限公司 吴泉江 | | 时间 | 2020 年 5 月 22 | 日下午 | | 地点 | 公司会议室 | | | 上市公司接待人 | 副总经理兼董事会秘书洪彦女士 | | | 员姓名 | | 董事会办公室证券专员尤雅、冯清清 | ...

证券代码：002626 证券简称：金达威 编号：20170831 | --- | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------------------|----------------------------------------------------|-------|------------| | | | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 参与单位名称及 人员姓名 | 民生证券股份有限公司 | 研究院 化工行业分析师 | | 陈煜 | | 时间 2017 | 年 8 月 31 日下午 | | | | | 地点 公司会议室 | | | | | | 上市公司接待人 员姓名 | ...

证券代码：002626 证券简称：金达威 厦门金达威集团股份有限公司投资者关系活动记录表 编号：20170713 | --- | --- | --- | --- | |-----------------------|------------------------------------|-------------------------|--------------------| | | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | | 类别 | □媒体采访 □业绩说明会 | | | | | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称及 | 招商证券有限责任公司 | 研究发展中心 | 化工行业高级分析师 | | 人员姓名 | 于庭泽 | | | | | 天风证券股份有限公司 | 研究所 医药行业分析师 | 王金成 | | | 东北证券股份有限公司 | 机构部经理 邱华熹 | | | | 东北证券股份有限公司 | 食品饮料行业首席分析师 | 李强 | | | 东北证券股份有限公司 ...